We are live on ! Find out more
RIGL icon

Rigel Pharmaceuticals
RIGL

135 hedge funds and large institutions have $503M invested in Rigel Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 33 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

45% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 33

22% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 18

12% more capital invested

Capital invested by funds: $447M → $503M (+$55.7M)

3% more funds holding

Funds holding: 131 → 135 (+4)

0.25% less ownership

Funds ownership: 9.65% → 9.41% (-0.25%)

45% less call options, than puts

Call options by funds: $788K | Put options by funds: $1.43M

Holders
135
Holders Change
+4
Holders Change %
+3.05%
% of All Funds
3.09%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
22
Increased
48
Reduced
33
Closed
18
Calls
$788K
Puts
$1.43M
Net Calls
-$645K
Net Calls Change
-$694K

Top Buyers

1
Millennium Management
Millennium Management
New York
+$13M
2
TA
Tamarack Advisers
California
+$5.78M
3
Morgan Stanley
Morgan Stanley
New York
+$3.78M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$3.02M
5
SI
Sofinnova Investments
California
+$2.97M

Top Sellers

1
MWNA
Marshall Wace North America
New York
-$11.5M
2
GPP
Great Point Partners
Connecticut
-$9.64M
3
SCM
Stonepine Capital Management
Oregon
-$4.24M
4
JP Morgan Chase
JP Morgan Chase
New York
-$3.82M
5
BBA
Baker Bros. Advisors
New York
-$2.95M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$80.1M +$1.29M +42,948 +2%
Wellington Management Group
2
Wellington Management Group
Massachusetts
$74.7M +$2.4M +80,088 +4%
BlackRock
3
BlackRock
New York
$43.8M +$729K +24,273 +2%
Millennium Management
4
Millennium Management
New York
$24.5M +$13M +433,172 +131%
Vanguard Group
5
Vanguard Group
Pennsylvania
$23.8M +$140K +4,678 +0.6%
State Street
6
State Street
Massachusetts
$23.1M -$2.37M -79,078 -10%
Citadel Advisors
7
Citadel Advisors
Florida
$17.8M -$1.89M -62,864 -10%
O
8
OppenheimerFunds
New York
$16.1M – – –
TA
9
Tamarack Advisers
California
$14.6M +$5.78M +192,500 +73%
T. Rowe Price Associates
10
T. Rowe Price Associates
Maryland
$14.6M +$3.02M +100,627 +28%
RSCM
11
Rock Springs Capital Management
Maryland
$13.2M +$525K +17,500 +4%
PAI
12
Palo Alto Investors
California
$12.7M – – –
SI
13
Sofinnova Investments
California
$10.5M +$2.97M +98,820 +43%
NMC
14
NEA Management Company
Maryland
$10.4M – – –
Morgan Stanley
15
Morgan Stanley
New York
$8.7M +$3.78M +126,072 +87%
BC
16
Boxer Capital
California
$7.45M – – –
CS
17
Candriam SCA
Luxembourg
$7.28M +$2.1M +69,800 +44%
RPAM
18
Rhenman & Partners Asset Management
Sweden
$6.79M +$1.23M +41,071 +24%
Goldman Sachs
19
Goldman Sachs
New York
$6.76M +$367K +12,234 +6%
Northern Trust
20
Northern Trust
Illinois
$6.59M +$168K +5,598 +3%
Hudson Bay Capital Management
21
Hudson Bay Capital Management
Connecticut
$6.28M -$135K -4,500 -2%
SCM
22
Sio Capital Management
New York
$5.92M +$1.34M +44,488 +32%
Geode Capital Management
23
Geode Capital Management
Massachusetts
$5.29M +$4.56K +152 +0.1%
Deutsche Bank
24
Deutsche Bank
Germany
$5.23M -$1.05K -35 -0%
Macquarie Group
25
Macquarie Group
Australia
$5.14M – – –
1
2 3 4 5

RIGL Hedge Fund Activity: Q3 2018 in Review

135 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2018, worth a combined $503M — up 12% from $447M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new RIGL positions and 18 closed out — a net gain of 4 holders — while 48 added to existing stakes and 33 trimmed.

The largest buyer was Millennium Management, adding an estimated $13M. The largest seller was Marshall Wace North America, cutting an estimated $11.5M.

  • 135 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2018, up from 131 in Q2 2018.
  • Funds reported $503M of Rigel Pharmaceuticals stock for Q3 2018, up 12% quarter-over-quarter.
  • 22 funds opened new Rigel Pharmaceuticals positions in Q3 2018 and 18 closed out, a net change of +4 holders.
  • The largest Rigel Pharmaceuticals buyer in Q3 2018 was Millennium Management, an estimated $13M added.
  • The largest Rigel Pharmaceuticals seller in Q3 2018 was Marshall Wace North America, an estimated $11.5M sold.

Based on aggregated 13F filings for Q3 2018.